Publications by authors named "Charles Lynde"
Acne vulgaris affects approximately 80% of young adults and adolescents in the world. Acne presents as comedones, pustules, papules, and nodules on the face, chest, shoulders, or back. It can lead to a significant decrease in quality of life with a high risk of associated depression and anxiety.
View Article and Find Full Text PDFBackground: Amlitelimab, a fully human nondepleting mAb targeting OX40 ligand on antigen-presenting cells, could prevent T-cell-driven inflammation seen in atopic dermatitis (AD).
Objective: This trial evaluated the efficacy and safety of amlitelimab in adults with AD.
Methods: In this 2-part, phase 2b, randomized, double-blinded placebo-controlled trial (ClinicalTrials.
Article Synopsis
- This study investigates the effectiveness and safety of ritlecitinib, a treatment for alopecia areata (AA), over 48 weeks in patients with varying responses by Week 24.
- Results showed that over 85% of patients who had good responses at Week 24 maintained their improvement, while some nonresponders also began to show better results by Week 48.
- The study had a small sample size, but it concludes that ritlecitinib can lead to sustained hair regrowth in many patients with AA.
Considerations for defining and diagnosing generalized pustular psoriasis.
J Eur Acad Dermatol Venereol
September 2024
Article Synopsis
- Generalized pustular psoriasis (GPP) is a rare skin disease that causes painful bumps and redness all over the body, and it can be really serious if not treated.
- GPP can come and go, but sometimes the symptoms can last a long time, and it's important for doctors to know about it.
- This paper wants to help more people recognize GPP so that it can be diagnosed and treated faster.
Importance: New, effective, and well-tolerated oral therapies are needed for treating psoriasis. Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, is a potential new oral treatment for this disease.
Objective: To assess the efficacy, safety, and tolerability of zasocitinib in patients with moderate to severe plaque psoriasis.
Oral Janus kinase inhibitors (JAKi), a class of advanced targeted systemic therapy, have demonstrated efficacy and safety in the treatment of moderate-to-severe atopic dermatitis (AD). Like other small molecules, oral JAKi have the potential for off-target effects including laboratory-related adverse events (AEs). Product labels for oral JAKi recommend an initial laboratory assessment and follow-up 4-12 weeks later to monitor for potential changes, based on evidence from clinical trials across therapeutic indications for oral JAKi, which may not reflect a population of moderate-to-severe AD patients typically seen in routine clinical practice.
View Article and Find Full Text PDFBackground: In the Nordic European Countries, cancer is the leading cause of death. The last decade has brought revolutionizing cancer treatments including immune checkpoint inhibitors (ICIs). Patients on ICIs have a high risk of developing cutaneous immune-related adverse events.
View Article and Find Full Text PDFArticle Synopsis
- Alopecia areata (AA) is a hair loss disorder that significantly affects quality of life, and studies have shown that the JAK inhibitor deuruxolitinib can promote hair regrowth in affected individuals.
- A Phase 3 trial tested deuruxolitinib in adults aged 18-65 with severe hair loss, finding that a significant percentage of patients experienced notable improvements in hair regrowth compared to a placebo.
- Although the treatment was generally well-tolerated with mostly mild side effects, further research is needed to assess long-term safety and the effects of stopping the treatment.
Article Synopsis
- Cendakimab is a treatment that targets and inhibits interleukin-13 (IL-13), which plays a role in the development of atopic dermatitis (AD), and is being studied for its effectiveness in treating this condition compared to a placebo.
- A phase 2 clinical trial involved 221 adult participants with moderate to severe AD who had not responded well to topical treatments, with patients receiving different doses of cendakimab or a placebo from May 2021 to November 2022.
- Results showed that the highest dose of cendakimab (720 mg, once weekly) significantly improved eczema symptoms compared to placebo, while other dosages did not achieve statistical significance, indicating potential for cend
Introduction: Certolizumab pegol (CZP) is an anti-tumor necrosis factor alpha (TNFα) approved for the treatment of moderate to severe plaque psoriasis (PSO). However, data on its real-world use is currently limited. The objective of this study was to describe the 1-year real-world effectiveness of CZP, its impact on health-related quality of life (HRQoL), and safety outcomes in patients with moderate to severe PSO in multi-country settings.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to analyze how well biologic drugs (IL-23 and IL-17 inhibitors) work for treating psoriasis in patients aged 65 and older compared to younger patients.
- It found that elderly patients had a higher risk of discontinuing treatment, especially with IL-23 inhibitors, while IL-17 inhibitors didn't show a significant difference.
- Additionally, factors like previous treatments influenced the likelihood of continuing or stopping the medication in elderly patients.
Secukinumab is a fully human IgG1 antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin-17A. Secukinumab is an effective and well-tolerated treatment for plaque psoriasis. There is a limited real-word evidence for dose optimisation of secukinumab based on clinical response.
View Article and Find Full Text PDFArticle Synopsis
- * Participants who received crisaborole showed a statistically significant greater ability to maintain their skin improvement, particularly during weeks 4 to 36 of the study.
- * Overall, the treatment was effective in both adults and children, with fewer flare occurrences in those taking crisaborole and a similar duration of flare periods compared to the vehicle group.
Background: Acne vulgaris is an inflammatory skin condition that is associated with poor acne health literacy. Diminished acne health literacy leads to delays in the access of health care, resulting in mismanagement, disfigurement, and psychosocial morbidity. This study evaluates the potential role of early acne education in young adolescent populations to improve acne health literacy and facilitate help-seeking behavior.
View Article and Find Full Text PDFArticle Synopsis
- * The Nordic European Cutaneous Oncodermatology Management (NECOM) project aims to enhance the care of cancer patients by establishing guidelines to prevent and manage skin-related side effects from cancer treatments, focusing on acute radiation dermatitis (ARD).
- * The NECOM 3 algorithm provides a step-by-step approach for healthcare providers, starting with skin-preserving therapies, to assess and treat RD, emphasizing the importance of patient education to improve quality of life and prevent treatment disruptions.
Article Synopsis
- Prurigo nodularis is a chronic skin disease causing intense itching, and nemolizumab, an IL-31 receptor antagonist, targets its underlying mechanisms.* -
- In a phase 3 trial, 274 adults with moderate-to-severe prurigo nodularis were given nemolizumab or a placebo for 16 weeks, showing significant improvements in itch and overall skin condition.* -
- Results revealed that 56.3% of the nemolizumab group reported reduced itching compared to 20.9% in the placebo group, with similar trends observed for other secondary outcomes, demonstrating its efficacy (P<0.001).*
Background: Genital psoriasis can be stigmatizing, is highly prevalent among patients with psoriasis, and has limited treatment options. Apremilast is a unique oral immunomodulating phosphodiesterase 4 inhibitor approved for psoriasis treatment.
Objective: To assess the efficacy and safety of apremilast 30 mg twice daily in patients with genital psoriasis.
Background: Not much is known about the burden of palmoplantar pustulosis (PPP).
Objectives: To document the burden of PPP in Canada, and to compare with psoriasis vulgaris (PV).
Methods: Adult Canadians (excluding the province of Quebec) hospitalized or visiting an emergency department (ED) or hospital-/community-based clinic between April 1, 2007, and March 31, 2020, with a diagnostic code indicating PPP (ICD-10-CA: L40.
Background: Psoriasis is a chronic immune-mediated dermatologic disorder with multisystemic comorbidities, which is effectively treated with a range of prescription therapies. Studies have reported epidermal barrier abnormalities in the lesional skin of psoriasis patients; however, there is currently insufficient information about skin barrier function in psoriasis patients. This review discusses the potential role of gentle cleansers and moisturizers in the management of psoriasis and in promoting a healthy skin barrier.
View Article and Find Full Text PDFArticle Synopsis
- The ALLEGRO-2b/3 clinical trial tested the effectiveness and safety of ritlecitinib, a daily pill for treating alopecia areata (AA), an autoimmune disease leading to hair loss.
- The study involved adults and adolescents, with participants taking ritlecitinib showing significantly more hair regrowth compared to a placebo after 24 weeks, with improvements observed on the scalp, eyebrows, and eyelashes.
- Ritlecitinib was found to be an effective and well-tolerated treatment for 48 weeks, with side effects being similar in both ritlecitinib and placebo groups, mostly mild to moderate.
Article Synopsis
- The study aimed to assess the burden of generalized pustular psoriasis (GPP) in Canada and compare it to psoriasis vulgaris (PV) using national health data from 2007 to 2020.
- Results showed that patients with GPP had significantly higher medical costs and mortality rates compared to those with PV, with mean costs of $2393 for GPP versus $222 for PV over 10 years.
- Limitations included the lack of physician and prescription drug data, which may affect the completeness of the findings.